Independent fund research. Built on SEC filings.

How we research funds

ETF · Leveraged & Inverse · Direxion

Direxion Daily LLY Bull 2X ETF (ELIL)

Ticker ELIL · · Holdings as of Jul 31, 2026

Expense ratio
1.07%$107/yr per $10k
Net assets
$18.3Mall share classes
Holdings
9

Bottom line

Is ELIL a good fund? The bottom line

ELIL is a managed leveraged & inverse ETF from Direxion.

Annual fees run 1.07% — about $107 a year on every $10,000 invested, cheaper than 64% of leveraged & inverse funds we track.

With $18.3 million in net assets and 9 holdings, its largest position is Goldman Sachs Liq Es Fd A (32.5%) and the top 10 make up 96.1% of the portfolio.

What to watch

  • Concentrated: top 10 holdings are 96.1% of assets
  • Small fund ($18.3 million) — small funds are likelier to close

Updated Nov 19, 2026

What ELIL invests in

The Fund seeks daily investment results, before fees and expenses, of 200% of the daily performance of LLY. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day.

The Fund, under normal circumstances, invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of LLY and financial instruments, such as swap agreements and options, that, in combination, provide 2X daily leveraged exposure to LLY, consistent with the Funds investment objective. The financial instrument in which the Fund most commonly invests is swap agreements, which are intended to produce economically leveraged investment results. Eli Lilly and Company is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines in various therapeutic areas, including neuroscience, endocrinology, oncology, cardiovascular diseases, and immunology. Its portfolio encompasses a wide range of prescription drugs, biologics, and animal health products. LLY is registered under the Securities Exchange…

From the fund's prospectus (filed Mar 3, 2026).

What ELIL costs

On a $10,000 investment, ELIL's 1.07% expense ratio costs about $107 a year. The prospectus estimates $1,558 in total costs over 10 years (assuming 5% annual returns). The median leveraged & inverse fund charges 1.31%.

See the full ELIL fee table →

ELIL top 10 holdings

#Holding% of fund
1Goldman Sachs Liq Es Fd A32.52%
2Dreyfus25.97%
3Dreyfus15.35%
4Eli Lilly & Company LLY15.09%
5Goldman Financial14.01%
6N/a0.82%
7N/a0.17%
8N/a-2.96%
9N/a-4.85%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 96.1% of the fund. See all top 25 holdings and asset mix →

Alternatives to ELIL

More funds like ELIL →

ELIL FAQ

What is the expense ratio of ELIL?
ELIL's expense ratio is 1.07%, which works out to about $107 a year for every $10,000 invested. The prospectus estimates total costs of $1,558 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is ELIL a good investment?
It depends on your goals, but the data points to: concentrated: top 10 holdings are 96.1% of assets; small fund ($18.3 million) — small funds are likelier to close. This is general information, not personalized advice.
What does ELIL hold?
ELIL's largest holdings are Goldman Sachs Liq Es Fd A (32.5%), Dreyfus (26.0%), Dreyfus (15.3%), Eli Lilly & Company (15.1%), Goldman Financial (14.0%). It holds 9 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
Who manages ELIL?
ELIL is offered by Direxion through Direxion Shares ETF Trust.